Tumor-infiltrating Lymphocytes-based Antibody Discovery Service

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Specific antibodies produced by tumor-infiltrating lymphocyte B cells could recognize tumor cells and activate a wide range of immune effector functions. Creative Biolabs is a leader in antibody discovery, providing biotech and pharmaceutical companies with end-to-end tumor-infiltrating lymphocytes-based antibody discovery services.

Background

Antibodies used to carry drugs or initiate human immune responses are already proven therapies for patients in modern clinical oncology. The monoclonal antibody technique advanced the development of targeted cancer therapies. However, the use of mouse monoclonal antibodies is restricted due to the induced anti-mouse immune response in the human body.

Tumor-infiltrating immune cells either promote or inhibit tumor growth, with the antitumor function derived in part from B cells' antibody production capacity. There is substantial evidence that tumor-infiltrating lymphocyte B cells (TIL-B) are activated by tumor cells, resulting in the production of specific antibodies that bind to tumor cells. It reveals that antibodies should be discovered from the immunoglobulin repertoire of tumor tissues affected by cancer cells. TIL-B-based antibodies either kill tumor cells via antibody-dependent cell-mediated cytotoxicity (ADCC) or induce complement-dependent cytotoxicity (CDC).

Fig. 1 Workflow of the tumor-infiltrating B lymphocyte (TIL-B) used to obtain tumor antigen-specific antibody fragments. (Kotlan, 2018)

Services at Creative Biolabs

We developed a comprehensive solution to discover fully human antibodies in tumor-infiltrating lymphocytes derived from cancer patients based on a thorough investigation of the interaction between the immune system and cancer cells.

Cloning antibody fragments in the TIL-B cell antibody repertoire

We were able to successfully obtain antibodies derived from tumor-infiltrating lymphocyte B cells by leveraging patients' natural immune response against tumor antigens. To create human Fab libraries, the variable regions of IgG1, IgG2, and IgA subclasses were amplified from cDNA templates using various molecular biological and biotechnological processes.

Phage display

Phage display is a less expensive and faster method for obtaining tumor-binding antibody fragments from B cells, allowing for the creation of large human recombinant antibody libraries. The antibody was expressed on the phage's surface in scFv format, making it easier to select and screen specific human antibodies that recognize various tumor cells. Furthermore, phage display produces clones with higher affinity by constructing mutant antibody libraries.

Selecting specific antitumor antibodies

To select tumor-specific antibodies for several rounds of selection, we panned these libraries against living cancer cells as well as common tumor surface antigens. We investigated scFv reactivity using enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, and fluorescence-activated cell sorting (FACS).

Creative Biolabs is a leader in antibody discovery, providing tumor-infiltrating lymphocyte-based antibody discovery services tailored to your specific needs. Our experienced technical experts work with you to accelerate your program by providing the right antibody with the required binding capacity, specificity, and affinity. Our TIL-B-based antibody discovery service will undoubtedly aid in the development of novel and more effective anticancer immunotherapies. Please contact us to learn how we can be involved in your projects.

Reference

Kotlan, B.; et al. Challenging tumour immunological techniques that help to track cancer stem cells in malignant melanomas and other solid tumours. Contemporary oncology. vol. 22,1A (2018): 41-47.